Passa al contenuto
Merck
Tutte le immagini(1)

Key Documents

Altri documenti

Y0000271

Oxaliplatin

European Pharmacopoeia (EP) Reference Standard

Sinonimo/i:

[SP-4-2-(1R-trans)]-(1,2-Cyclohexanediamine-N,N′)[ethanedioata(2--)-O,O’]platinum

Autenticatiper visualizzare i prezzi riservati alla tua organizzazione & contrattuali
Tutte le immagini(1)

About This Item

Formula empirica (notazione di Hill):
C8H14N2O4Pt
Numero CAS:
61825-94-3
Peso molecolare:
397.29
Numero MDL:
MFCD00866327
Codice UNSPSC:
41116107
ID PubChem:
329830895
NACRES:
NA.24

Grado

pharmaceutical primary standard

Famiglia di API

oxaliplatin

Produttore/marchio commerciale

EDQM

applicazioni

pharmaceutical (small molecule)

Formato

neat

Temperatura di conservazione

2-8°C

Stringa SMILE

O=C1O[Pt]OC1=O.N[C@@H]2CCCC[C@H]2N

InChI

1S/C6H14N2.C2H2O4.Pt/c7-5-3-1-2-4-6(5)8;3-1(4)2(5)6;/h5-6H,1-4,7-8H2;(H,3,4)(H,5,6);/q;;+2/p-2/t5-,6-;;/m1../s1
ZROHGHOFXNOHSO-BNTLRKBRSA-L

Cerchi prodotti simili? Visita Guida al confronto tra prodotti

Categorie correlate

Descrizione generale

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the Issuing Pharmacopoeia. For further information and support please go to the website of the issuing Pharmacopoeia.

Applicazioni

Oxaliplatin EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Confezionamento

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Altre note

Sales restrictions may apply.

Prodotti correlati

N° Catalogo
Descrizione
Determinazione del prezzo

Y0000275

Dichlorodiaminocyclohexaneplatinum, European Pharmacopoeia (EP) Reference Standard

Y0000273

Oxaliplatin impurity C, European Pharmacopoeia (EP) Reference Standard

Y0000274

Oxaliplatin impurity D, European Pharmacopoeia (EP) Reference Standard

Y0000272

Oxaliplatin impurity B, European Pharmacopoeia (EP) Reference Standard

1481204

Oxaliplatin, United States Pharmacopeia (USP) Reference Standard

1481226

Oxaliplatin Related Compound B, United States Pharmacopeia (USP) Reference Standard

1481215

Oxaliplatin Related Compound A, United States Pharmacopeia (USP) Reference Standard

1481237

Oxaliplatin Related Compound C, United States Pharmacopeia (USP) Reference Standard

1481248

Oxaliplatin Related Compound D, United States Pharmacopeia (USP) Reference Standard

1481306

Oxaliplatin System Suitability, United States Pharmacopeia (USP) Reference Standard

1481260

Oxaliplatin Related Compound F, United States Pharmacopeia (USP) Reference Standard

PHR2545

Oxaliplatin Related Compound A, Pharmaceutical Secondary Standard; Certified Reference Material

Pittogrammi

CorrosionHealth hazard
GHS05,GHS08

Avvertenze

Danger

Classi di pericolo

Carc. 2 - Eye Dam. 1 - Lact. - Muta. 2 - Repr. 1B - Resp. Sens. 1B - Skin Sens. 1 - STOT RE 1

Codice della classe di stoccaggio

6.1C - Combustible, acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

Classe di pericolosità dell'acqua (WGK)

WGK 3

Punto d’infiammabilità (°F)

Not applicable

Punto d’infiammabilità (°C)

Not applicable

Scegli una delle versioni più recenti:

Certificati d'analisi (COA)

Lot/Batch Number

Ci dispiace, ma al momento non ci sono COA disponibili online per questo prodotto.

Se ti serve aiuto, non esitare a contattarci Servizio Clienti

Possiedi già questo prodotto?

I documenti relativi ai prodotti acquistati recentemente sono disponibili nell’Archivio dei documenti.

Visita l’Archivio dei documenti

I clienti hanno visto anche

Slide 1 of 8

1 of 8

5-Fluorouracil ≥99% (HPLC), powder

Sigma-Aldrich

F6627

5-Fluorouracil

Irinotecan hydrochloride topoisomerase inhibitor

Sigma-Aldrich

I1406

Irinotecan hydrochloride

Calcium folinate European Pharmacopoeia (EP) Reference Standard

C0250000

Calcium folinate

Carboplatin

Sigma-Aldrich

C2538

Carboplatin

vibrant-m

Y0001832

Irinotecan hydrochloride trihydrate

Cisplatin European Pharmacopoeia (EP) Reference Standard

C2210000

Cisplatin

Supelco

Supelco

PHR1541

Leucovorin Calcium

Dichloro(1,2-diaminocyclohexane)platinum(II)

Sigma-Aldrich

404322

Dichloro(1,2-diaminocyclohexane)platinum(II)

Catia Moutinho et al.
Journal of the National Cancer Institute, 106(1), djt322-djt322 (2013-11-26)
A major problem in cancer chemotherapy is the existence of primary resistance and/or the acquisition of secondary resistance. Many cellular defects contribute to chemoresistance, but epigenetic changes can also be a cause. A DNA methylation microarray was used to identify
Bernard Nordlinger et al.
The Lancet. Oncology, 14(12), 1208-1215 (2013-10-15)
Previous results of the EORTC intergroup trial 40983 showed that perioperative chemotherapy with FOLFOX4 (folinic acid, fluorouracil, and oxaliplatin) increases progression-free survival (PFS) compared with surgery alone for patients with initially resectable liver metastases from colorectal cancer. Here we present
Noriho Iida et al.
Science (New York, N.Y.), 342(6161), 967-970 (2013-11-23)
The gut microbiota influences both local and systemic inflammation. Inflammation contributes to development, progression, and treatment of cancer, but it remains unclear whether commensal bacteria affect inflammation in the sterile tumor microenvironment. Here, we show that disruption of the microbiota
Roser Velasco et al.
Journal of neurology, neurosurgery, and psychiatry, 85(4), 392-398 (2013-07-03)
Peripheral neuropathy ranks among the most common dose-limiting and disabling side-effect of oxaliplatin (OXA)-based chemotherapy. The aim of this prospective, multicentre study was to define early clinical and neurophysiological markers that may help to identify patients at risk of developing
Kristina Jansson et al.
Environmental and molecular mutagenesis, 54(5), 327-337 (2013-05-17)
The highly conserved DNA glycosylase MutY is implicated in repair of oxidative DNA damage, in particular in removing adenines misincorporated opposite 7,8-dihydro-8-oxoguanine (8-oxo-G). The MutY homologues (MutYH) physically associate with proteins implicated in replication, DNA repair, and checkpoint signaling, specifically
Visualizza tutti i documenti correlati

Il team dei nostri ricercatori vanta grande esperienza in tutte le aree della ricerca quali Life Science, scienza dei materiali, sintesi chimica, cromatografia, discipline analitiche, ecc..

Contatta l'Assistenza Tecnica.